News | April 01, 2025
Lonza implements streamlined operating model
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
_256_384.jpg){kind=logo}
Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
Subscribe To Our Newsletter & Stay Updated
